Karyopharm Therapeutics Inc.
NASDAQ:KPTIBiotechnology
-$0.34 today
- Market cap
- $158.87M
- Beta
- 0.82
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$8.86
Volume 0.67M
Average 0.85M
KPTI Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Karyopharm Therapeutics Inc.NASDAQ: KPTI
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin holds steady near 96.1%
Gross margin was 96.1% in Q1 FY2026, up 0.5 pp from a year earlier. On a trailing-twelve-month basis it was 96.0%, down 0.1 pp year over year. Over 3 fiscal years it narrowed by 0.8 pp.
Context
- Gross margin widened in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 95.9%
- Year-over-year change
- +0.1pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 95.9% | +0.1pp |
| FY2024 | 2024-12-31 | 95.9% | -0.8pp |
| FY2023 | 2023-12-31 | 96.6% | -0.1pp |
| FY2022 | 2022-12-31 | 96.7% | -1.7pp |
| FY2021 | 2021-12-31 | 98.4% | — |
Gross Margin vs competitors
How KPTI compares with its peers on the latest reported figures
- KPTI's LTM Mar 2026 gross margin of 96.0% is the 2nd highest of the 3 companies compared; the peer median is 89.7%.
- Its year-over-year change of -0.1 pp is the 2nd highest of 3, against a peer median of -0.6 pp.
- Over three fiscal years its change of -0.8 pp compares with a peer median of +0.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | 100.0% | +0.0 pp | +0.0 pp | |
| LTM Mar 2026 | 96.0% | -0.1 pp | -0.8 pp | |
| LTM Mar 2026 | 79.4% | -1.2 pp | — | |
| FY2025 | — | — | — | |
| Peer median (excluding KPTI) | 89.7% | -0.6 pp | +0.0 pp | |
Competitors are the stored peer set for KPTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 209.82M | 157.07M | 146.03M | 145.24M | 146.07M |
| Cost of Revenue | 3.4M | 5.21M | 4.94M | 6.01M | 5.95M |
| Gross Profit | 206.42M | 151.86M | 141.09M | 139.23M | 140.12M |
| Gross Margin | 98.4% | 96.7% | 96.6% | 95.9% | 95.9% |
| Research & Development | 160.84M | 148.66M | 138.75M | 143.23M | 125.62M |
| Selling, General & Admin | 143.85M | 145.4M | 131.88M | 115.44M | 105.21M |
| Operating Expenses | 304.69M | 294.06M | 270.63M | 258.67M | 230.83M |
| Depreciation & Amortization | 789K | 621K | 530K | 340K | 296K |
| EBITDA | (96.99M) | (139.31M) | (118.42M) | (38.6M) | (149.85M) |
| EBITDA Margin | -46.2% | -88.7% | -81.1% | -26.6% | -102.6% |
| Operating Income | (98.27M) | (142.2M) | (129.54M) | (119.44M) | (90.71M) |
| Operating Margin | -46.8% | -90.5% | -88.7% | -82.2% | -62.1% |
| Interest Income | 582K | 2.36M | 10.94M | 7.4M | 2.77M |
| Interest Expense | 26.05M | 25M | 23.82M | 37.42M | 45.85M |
| Other Income / Expenses | (25.55M) | (22.72M) | (13.24M) | 43.08M | (105.29M) |
| Income Before Tax | (123.82M) | (164.92M) | (142.78M) | (76.37M) | (196M) |
| Pre-Tax Margin | -59.0% | -105.0% | -97.8% | -52.6% | -134.2% |
| Income Tax Expense | 268K | 369K | 323K | 57K | 43K |
| Net Income | (124.09M) | (165.29M) | (143.1M) | (76.42M) | (196.04M) |
| Net Margin | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% |
| EPS (Basic) | (24.75) | (30.28) | (18.79) | (9.41) | (17.93) |
| EPS (Diluted) | (24.75) | (30.28) | (18.79) | (9.41) | (17.93) |
| Weighted Avg Shares | 5.01M | 5.46M | 7.61M | 8.12M | 10.94M |
| Weighted Avg Shares (Diluted) | 5.01M | 5.46M | 7.61M | 8.12M | 10.94M |
Karyopharm Therapeutics Inc.
NASDAQ:KPTI
Intrinsic Alpha fair value
Locked
Current Price
$7.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.